Article Text

Download PDFPDF

1 The river trial: a trial of venous sinus stenting with the river stent in idiopathic intracranial hypertension (IIH)
  1. A Patsalides
  1. Weill Cornell Medical College, New York, NY


Introduction Venous sinus Stenting (VSS) is an emerging treatment for patients with IIH. However, VSS is currently performed with stents designed for stenting atherosclerotic arterial stenosis. The River™ stent has been specifically designed for treating the stenosis of the transverse-sigmoid sinuses and has the following characteristics: easy navigability through the tortuosity of the sigmoid sinus; 7 cm long length to cover the venous sinuses from the torcula to the mid sigmoid segment; two zones of radial force to address the intrinsic stenosis at the sigmoid transverse junction (stiffer zone) and extrinsic stenosis of the mid transverse sinus (softer zone); and large open cells to adapt to the triangular shape of the venous sinus without occluding cortical veins.

Methods The River trial is a single arm pivotal trial designed for HDE approval of the River™ stent (Serenity Medical Inc, Redwood City, CA). The trial will enroll 39 subjects in 7 clinical sites. Subjects must have proven IIH and >50% stenosis of the sigmoid-transverse sinus with pressure gradient >8 mm Hg. Subjects can be enrolled on visual criteria: visual field deficit from – 6 db to – 30 db resistant to medical therapy >2 weeks; or on headaches criteria: severe headaches defined by Headache Impact Test (HIT-6) >59 resistant to medical therapy >4 weeks. The patients need to be on dual antiplatelet therapy (aspirin and clopidogrel) for 3 months and aspirin monotherapy for 9 more months.

The primary safety endpoint is the rate of major adverse event (any neurological complication plus need for any surgical procedure for IIH) at 12 months. The primary efficacy endpoint is a composite at 12 months of clinical improvement and absence of significant venous stenosis. Secondary endpoints at 12 months include opening pressure on lumbar puncture, individual ophthalmology endpoints, change in pulsatile tinnitus, change in medications, change in quality of life scores.

Results Enrollment started in September 2018. Four sites are active at the time of submission of this abstract and three other sites are in the process of certification. Eleven subjects have been enrolled. In all 11 cases the catheterization with the River™ stent was extremely easy and the stent was deployed as expected. In two patients with severe stenosis from arachnoid granulation, post-stent angioplasty was performed. There was resolution of the trans-stenotic gradient in all cases. There was no stent-thrombosis. There was no impairment of flow in the cortical veins draining into the stented segment. There were no major neurological adverse events or device related complications.

None of the enrolled patients reached the 12-month follow-up time point and therefore we cannot report on primary and secondary endpoints but an update of the trial with intermediate clinical results will be presented at the conference.

Conclusion We provide early/interim results of the use of the River stent. This novel stent has been effective for the treatment of venous sinus stenosis without any short-term serious adverse events or device related complications.

Disclosures A. Patsalides: None.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.